自拟活血舒痹汤治疗急性心肌梗死PCI术后缺血再灌注损伤的临床研究

郑祥; 王审

doi:10.16766/j.cnki.issn.1674-4152.003026

自拟活血舒痹汤治疗急性心肌梗死PCI术后缺血再灌注损伤的临床研究

doi: 10.16766/j.cnki.issn.1674-4152.003026

郑祥^1, ,,
王审²

1.
温州市中西医结合医院心血管内科，浙江温州 325000
2.
浙江绿城心血管病医院心内科，浙江杭州 310000

基金项目:

浙江省中医药科技计划项目 2022ZB149

详细信息

通讯作者:
郑祥，E-mail: kinddoctorky@126.com

中图分类号: R542.22
计量
- 文章访问数: 121
- HTML全文浏览量: 20
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2023-02-13
- 网络出版日期: 2023-08-26

Clinical study of self-made Huoxue Shubi Decoction on the treatment of ischemia reperfusion injury after PCI in acute myocardial infarction

ZHENG Xiang^{1
, ,},
WANG Shen²

1.
Department of Cardiovascular Medicine, Wenzhou Integrated Hospital of Traditional Chinese and Western Medicine, Wenzhou, Zhejiang 325000, China

摘要

摘要: 目的探讨自拟活血舒痹汤对急性心肌梗死经皮冠状动脉介入术(PCI)后缺血再灌注损伤(IRI)的临床疗效、心室重塑、心血管不良事件的影响。方法选取2019年1月—2021年12月温州市中西医结合医院心血管内科急性心肌梗死PCI术后患者96例，根据随机数字表法，分为对照组(48例)和观察组(48例)。对照组给予阿司匹林和替格瑞洛治疗，观察组加服自拟活血舒痹汤治疗。比较2组临床疗效、中医证候积分、血小板聚集、心绞痛、心功能指标、心血管不良事件等。结果治疗2个月后，观察组有效率为95.83%(46/48)，对照组为79.17%(38/48)，2组比较差异有统计学意义(χ²=6.095, P=0.014)。治疗2个月后，观察组胸痛、心悸气短、乏力、自汗、舌质暗紫、脉虚无力等评分均低于对照组(均P＜0.05)。治疗2个月后，2组血小板聚集率、心绞痛均改善，观察组均优于对照组(均P＞0.05)；2组左室射血分数(LVEF)、左心室舒张末容积(LVEDV)、左心室收缩末容积(LVESV)均改善，观察组均优于对照组(均P＜0.05)；2组心血管不良事件发生率比较差异无统计学意义(P＞0.05)。结论在西医治疗基础上，加用自拟活血舒痹汤治疗急性心肌梗死PCI术后IRI效果显著，能促进症状改善，减少血小板聚集，缓解心肌重塑，且安全性高。
- 急性心肌梗死 /
- 经皮冠状动脉介入术 /
- 缺血再灌注损伤 /
- 联合治疗 /
- 气虚血瘀证
Abstract: Objective To explore the clinical efficacy, ventricular remodeling, and cardiovascular adverse events of self-made Huoxue Shubi Decoction on patients with ischemia-reperfusion injury (IRI) after percutaneous coronary intervention (PCI) in acute myocardial infarction. Methods A total of 96 patients with acute myocardial infarction after PCI surgery in the Department of Cardiovascular Medicine of Wenzhou Integrated Traditional Chinese and Western Medicine Hospital from January 2019 to December 2021 were selected. According to the random number table method, they were randomly divided into a control group and an observation group, with 48 cases each group. The control group was treated with aspirin and ticagrelor, while the observation group was treated with self-made Huoxue Shubi Decoction on the basis of the control group. The clinical efficacy, traditional Chinese medicine syndromes, platelet aggregation, angina pectoris, cardiac function indicators, and cardiovascular adverse events were compared between the two groups. Results After 2 months of treatment, the effective rate of the observation group was 95.83% (46/48), while the control group was 79.17% (38/48), with statistically significant (χ²=6.095, P=0.014). After two months of treatment, the scores of chest pain, palpitations, shortness of breath, fatigue, spontaneous sweating, dark purple tongue, and weak pulse in the observation group were lower than those in the control group (all P < 0.05). After 2 months of treatment, the platelet aggregation rate and angina in the two groups were improved and the observation group were better than the control group (all P > 0.05), the left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) in the two groups were improved and the observation group were better than the control group (all P < 0.05), and there was no statistically significant difference in the incidence of cardiovascular adverse events between the two groups (P > 0.05). Conclusion On the basis of Western medicine treatment, the addition of self-made Huoxue Shubi Decoction has a significant therapeutic effect on IRI after PCI in acute myocardial infarction. It can promote the improvement of symptoms, reduce platelet aggregation, relieve myocardial remodeling, and has high safety.
- Acute myocardial infarction /
- Percutaneous coronary intervention /
- Ischemia-reperfusion injury /
- Combination therapy /
- Qi deficiency and blood stasis syndrome

HTML全文

表 1 2组急性心肌梗死PCI术后患者一般资料比较

Table 1. Comparison of general data of patients with acute myocardial infarction after PCI in 2 groups

组别	例数	性别(例)		年龄(x±s，岁)	就诊时间[M(P₂₅, P₇₅)，h]	Killip分级(例)			基础疾病(例)
组别	例数	男性	女性	年龄(x±s，岁)	就诊时间[M(P₂₅, P₇₅)，h]	Ⅰ	Ⅱ	Ⅲ	高血压	高血脂	糖尿病
对照组	48	25	23	65.53±11.30	2.90(2.51，3.73)	13	28	7	36	19	15
观察组	48	28	20	64.91±12.66	3.02(2.65，3.59)	10	25	13	35	22	17
统计量		0.379^a		0.253^b	0.404^c	1.356^c			0.054^a	0.383^a	0.188^a
P值		0.538		0.801	0.688	0.175			0.816	0.536	0.665
注：^a为χ²值，^b为t值，^c为Z值。

下载: 导出CSV

表 2 2组急性心肌梗死PCI术后患者临床疗效比较[例(%)]

Table 2. Comparison of clinical efficacy between two groups of patients with acute myocardial infarction after PCI [cases (%)]

组别	例数	显效	缓解	无效	总有效
对照组	48	28(58.33)	10(20.83)	10(20.83)	38(79.17)
观察组	48	36(75.00)	10(20.83)	2(4.17)	46(95.83)
注：2组总有效率比较，χ²=6.095, P=0.014。

下载: 导出CSV

表 3 2组急性心肌梗死PCI术后患者中医临床症状量表积分比较(x±s，分)

Table 3. Comparison of TCM clinical symptom scale scores between the two groups of patients with acute myocardial infarction after PCI

组别	例数	胸痛		气短心悸		乏力
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	48	2.52±0.25	1.65±0.22^a	2.34±0.31	1.38±0.21^a	2.02±0.31	1.51±0.36^a
观察组	48	2.59±0.31	0.73±0.13^a	2.28±0.33	0.82±0.10^a	2.11±0.35	1.01±0.22^a
t值		1.218	24.943	0.918	16.681	1.334	8.211
P值		0.226	＜0.001	0.361	＜0.001	0.185	＜0.001

组别	例数	自汗		舌质暗紫		脉虚无力
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	48	2.22±0.45	1.65±0.32^a	2.50±0.40	1.40±0.22^a	2.31±0.30	1.21±0.25^a
观察组	48	2.17±0.33	1.01±0.28^a	2.44±0.38	0.72±0.09^a	2.20±0.28	0.07±0.15^a
t值		0.621	10.428	0.753	19.820	1.857	27.090
P值		0.536	＜0.001	0.453	＜0.001	0.066	＜0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 4 2组急性心肌梗死PCI术后患者血小板聚集率及心绞痛程度比较(x±s)

Table 4. The platelet aggregation rate and the degree of angina in patients with acute myocardial infarction after PCI were compared between the two groups (x±s)

组别	例数	血小板聚集率(%)		t值	P值	SAQ评分(分)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	48	72.64±9.27	43.35±5.29	19.013	＜0.001	272.32±51.68	387.46±58.71	10.199	＜0.001
观察组	48	71.33±9.36	32.19±4.87	25.701	＜0.001	283.51±53.79	415.60±65.32	10.815	＜0.001
t值		0.689	10.753			1.039	2.220
P值		0.493	＜0.001			0.301	0.029

下载: 导出CSV

表 5 2组急性心肌梗死PCI术后患者心功能指标比较(x±s)

Table 5. Comparison of cardiac function indexes between the two groups of patients with acute myocardial infarction after PCI (x±s)

组别	例数	LVEF(%)		LVEDV(mL)		LVESV(mL)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	48	48.62±5.33	52.15±6.27^a	135.32±15.21	120.39±10.35^a	85.24±5.37	65.39±5.20^a
观察组	48	47.69±4.49	56.33±6.79^a	135.68±13.76	115.95±9.21^a	84.69±5.10	60.81±4.68^a
t值		0.925	3.133	0.122	2.220	0.515	4.536
P值		0.358	0.002	0.904	0.029	0.608	＜0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 6 2组急性心肌梗死PCI术后患者心血管不良事件比较[例(%)]

Table 6. Comparison of cardiovascular adverse events between the two groups of patients with acute myocardial infarction after PCI [cases (%)]

组别	例数	严重心律失常	出血	再次心肌梗死	心力衰竭	死亡	合计
对照组	48	4(8.33)	2(4.17)	1(2.08)	1(2.08)	2(4.17)	10(20.83)
观察组	48	2(4.17)	2(4.17)	0	2(4.17)	1(2.08)	7(14.58)
注：2组不良事件总发生率比较，χ²=0.643，P=0.423。

下载: 导出CSV

参考文献(19)

[1]	LI S D, GAO X J, YANG J G, et al. Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry[J]. BMC Med, 2022, 20(1): 217. doi: 10.1186/s12916-022-02418-w
[2]	何文君, 张小芳, 金瑜, 等. 胸痛中心建设持续改进对急性ST段抬高型心肌梗死抢救时间及心血管不良事件的影响[J]. 中华全科医学, 2022, 20(9): 1603-1607. doi: 10.16766/j.cnki.issn.1674-4152.002659 HE W J, ZHANG X F, JIN Y, et al. Impact of continuous improvement in the construction of the chest-pain centre on the rescue time of acute ST segment elevated myocardial infarction and cardiovascular adverse events[J]. Chinese Journal of General Practice, 2022, 20(9): 1603-1607. doi: 10.16766/j.cnki.issn.1674-4152.002659
[3]	洪名扬, 富路. 冠心病心肌缺血再灌注损伤机制研究的进展[J]. 心血管康复医学杂志, 2022, 31(2): 241-245. https://www.cnki.com.cn/Article/CJFDTOTAL-XXGK202202026.htm HONG M Y, FU L. Research progress on mechanism of myocardial ischemia-reperfusion injury in coronary heart disease[J]. Chinese Journal of Cardiovascular Rehabilitation Medicine, 2022, 31(2): 241-245. https://www.cnki.com.cn/Article/CJFDTOTAL-XXGK202202026.htm
[4]	曹蛟, 张杼惠, 刘建和. 从中医"阳气亏虚, 痰瘀内阻"理论探讨中医药防治心肌缺血再灌注损伤的机制[J]. 世界科学技术-中医药现代化, 2021, 23(2): 510-515. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202102027.htm CAO J, ZHANG Z H, LIU J H. Discussion on the mechanism of myocardial ischemia-reperfusion injury in traditional Chinese medicine from the theory of "deficiency of Yang Qi, phlegm and blood stasis blocking the viscera"[J]. World Science and Technology - TCM modernization, 2021, 23(2): 510-515. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202102027.htm
[5]	龚艳君, 霍勇. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)解读[J]. 中国心血管病研究, 2019, 17(12): 1057-1061. doi: 10.3969/j.issn.1672-5301.2019.12.001 GONG Y J, HUO Y. Interpretation of the guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction(2019)[J]. Chinese Journal of Cardiovascular Research, 2019, 17(12): 1057-1061. doi: 10.3969/j.issn.1672-5301.2019.12.001
[6]	国家中医药管理局. 中医病证诊断疗效标准[M]. 南京: 南京大学出版社, 1994: 201-202. National Administration of Traditional Chinese Medicine. TCM disease diagnosis and curative effect criteria[M]. Nanjing: Nanjing University Press, 1994: 201-202.
[7]	MILWIDSKY A, GREIDINGER D, FRYDMAN S, et al. Echocardiographic Killip Classification[J]. J Am Soc Echocardiogr, 2022, 35(3): 287-294. doi: 10.1016/j.echo.2021.10.012
[8]	郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 233-237. ZHENG X Y. Guiding Principles for Clinical Research of New Chinese Medicine (Trial)[M]. Beijing: China Medical Science and Technology Press, 2002: 233-237.
[9]	DAMLUJI A A, VAN DIEPEN S, KATZ J N, et al. Mechanical complications of acute myocardial infarction: a scientific statement from the American Heart Association[J]. Circulation, 2021, 144(2): e16-e35. http://www.xueshufan.com/publication/3167258811
[10]	罗俊, 赵帅宗, 李雪源, 等. 中西医结合心脏康复在急性心肌梗死PCI术后患者中的疗效观察[J]. 浙江临床医学, 2022, 24(3): 373-375. LUO J, ZHAO S Z, LI X Y, et al. Observation of curative effect of cardiac rehabilitation combined with traditional Chinese and Western medicine in patients with acute myocardial infarction after PCI[J]. Zhejiang Clinical Medical Journal, 2022, 24(3): 373-375.
[11]	王磊, 郝季春, 马东, 等. 左卡尼汀联合rhBNP治疗急性心肌梗死PCI术后缺血再灌注损伤的临床研究[J]. 中西医结合心脑血管病杂志, 2021, 19(14): 2392-2395. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202114021.htm WANG L, HAO J C, MA D, et al. Clinical study of levocarnitine combined with rhBNP in the treatment of ischemic reperfusion injury after PCI in acute myocardial infarction[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2021, 19(14): 2392-2395. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202114021.htm
[12]	陈润都, 张颖倩, 佟伟, 等. 心肌内出血与心肌梗死后不良心室重构的关系研究进展[J]. 解放军医学杂志, 2022, 47(2): 186-191. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202202010.htm CHEN R D, ZHANG Y Q, TONG W, et al. Relationship between intramyocardial hemorrhage and adverse ventricular remodeling after myocardial infarction[J]. Medical Journal of Chinese People's Liberation Army, 2022, 47(2): 186-191. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202202010.htm
[13]	孟培培, 付广威, 张辉, 等. 浅析真心痛与别络痛[J]. 中西医结合心脑血管病杂志, 2022, 20(9): 1706-1708. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202209038.htm MENG P P, FU G W, ZHANG H, et al. Analysis of true pain and pain of other collaterals[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2022, 20(9): 1706-1708. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202209038.htm
[14]	李雪平, 许朝霞, 徐琎, 等. 冠状动脉粥样硬化性心脏病患者不同中医证候与危险因素的相关性研究[J]. 中华中医药杂志, 2019, 34(6): 2717-2720. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906104.htm LI X P, XU Z X, XU J, et al. Study on the correlation between different TCM syndromes and risk factors in patients with coronary heart disease[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2019, 34(6): 2717-2720. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906104.htm
[15]	冯妍, 王以新, 马涵英, 等. 冠状动脉粥样硬化性心脏病心力衰竭不同兼症及合并病中医治疗方案优化研究[J]. 中国医药, 2020, 15(8): 1192-1196. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202008010.htm FENG Y, WANG Y X, MA H Y, et al. Traditional Chinese medicine treating heart failure due to coronary heart disease with different symptoms and complications[J]. China Medicine, 2020, 15(8): 1192-1196. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202008010.htm
[16]	李盈盈, 张宇, 刘思鸿, 等. 瓜蒌薤白半夏汤研究文献可视化分析[J]. 中国中医药信息杂志, 2022, 29(5): 38-43. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202205007.htm LI Y Y, ZHANG Y, LIU S H, et al. Visualization Analysis on Literature about Gualou Xiebai Banxia Decoction[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2022, 29(5): 38-43. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202205007.htm
[17]	侯凯, 谭昊宇, 刘静, 等. 心肌缺血再灌注损伤的防治新靶点寻找及其研究进展[J]. 中国药科大学学报, 2022, 53(2): 164-170. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYD202202005.htm HOU K, TAN H Y, LIU J, et al. Advance of novel target strategies participating in myocardial ischemia reperfusion injury[J]. Journal of China Pharmaceutical University, 2022, 53(2): 164-170. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYD202202005.htm
[18]	李宁, 陈晓杰, 李金宝, 等. 益气活血方对急性心肌梗死术后气虚血瘀证患者血小板聚集及心室重构的影响[J]. 现代中西医结合杂志, 2022, 31(11): 1554-1557. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202211020.htm LI N, CHEN X J, LI J B, et al. Effect of Yiqi Huoxue Decoction on platelet aggregation and ventricular remodeling in patients with Qi-deficiency and blood-stasis syndrome after acute myocardial infarction[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2022, 31(11): 1554-1557. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202211020.htm
[19]	陈琦, 林子舒, 马天一, 等. 负荷量替格瑞洛联合丹红注射液防治急性前壁STEMI患者PCI后再灌注心律失常疗效及对心肌损伤指标的影响[J]. 现代中西医结合杂志, 2021, 30(23): 2555-2560. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202123011.htm CHEN Q, LIN Z S, MA T Y, et al. Efficacy of loading ticagrelor combined with Danhong injection in preventing and treating reperfusion arrhythmia after PCI in patients with acute anterior wall STEMI and its influence on myocardial injury indexes[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2021, 30(23): 2555-2560. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202123011.htm